[Bisphosphonates and osteonecrosis of the jaw].
Today, bisphosphonates are very frequently used to relieve patients suffering from various bone diseases, mainly bone metastases and osteoporosis. They have been associated with numerous cases of maxillar and mandibullar osteonecrosis, a severe affection characterized by a high morbidity and for which no consensual treatment has been found yet. After a short update, the authors reviewed indications for bisphosphonates and its pharmacological properties. The pathogenesis, predisposing factors, symptoms, and clinical evaluation of this particular necrosis are described. Preventive and therapeutic managements are suggested.
Saussez
S
S
Service d'anatomie, faculté de médecine et de pharmacie, université de Mons-Hainaut, Mons, Belgique. sven.saussez@umh.ac.be
Filleul
O
O
Loeb
I
I
D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000494:pharmacology; D016723:Bone Remodeling / Q000187:drug effects; D004164:Diphosphonates / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010010:Osteoclasts / Q000187:drug effects; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy
D050071:Bone Density Conservation Agents; D004164:Diphosphonates